Crossmark Global Holdings Inc. Lowers Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Crossmark Global Holdings Inc. trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,709 shares of the company’s stock after selling 865 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in IDEXX Laboratories were worth $1,534,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories during the third quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the period. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth approximately $31,000. Mowery & Schoenfeld Wealth Management LLC grew its stake in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in IDEXX Laboratories during the second quarter worth approximately $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 0.4 %

IDXX opened at $432.34 on Friday. The stock has a market capitalization of $35.40 billion, a PE ratio of 41.69, a P/E/G ratio of 3.60 and a beta of 1.36. The firm’s fifty day moving average price is $423.28 and its 200 day moving average price is $456.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.53 earnings per share. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.11% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on IDXX shares. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Piper Sandler restated a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Finally, Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $523.86.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.